CUE Straddle Strategy
CUE (Cue Biopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine.
CUE (Cue Biopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $66.7M, a beta of 2.55 versus the broader market, a 52-week range of 4.98-41.42, average daily share volume of 748K, a public-listing history dating back to 2018, approximately 41 full-time employees. These structural characteristics shape how CUE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.55 indicates CUE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a straddle on CUE?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current CUE snapshot
As of June 30, 2026, spot at $30.36, ATM IV 43.80%, IV rank 10.60%, expected move 12.56%. The straddle on CUE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this straddle structure on CUE specifically: CUE IV at 43.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a CUE straddle, with a market-implied 1-standard-deviation move of approximately 12.56% (roughly $3.81 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CUE expiries trade a higher absolute premium for lower per-day decay. Position sizing on CUE should anchor to the underlying notional of $30.36 per share and to the trader's directional view on CUE stock.
CUE straddle setup
The CUE straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CUE near $30.36, the first option leg uses a $30.36 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CUE chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CUE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $30.36 | N/A |
| Buy 1 | Put | $30.36 | N/A |
CUE straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
CUE straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on CUE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on CUE
Straddles on CUE are pure-volatility plays that profit from large moves in either direction; traders typically buy CUE straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
CUE thesis for this straddle
The market-implied 1-standard-deviation range for CUE extends from approximately $26.55 on the downside to $34.17 on the upside. A CUE long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current CUE IV rank near 10.60% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CUE at 43.80%. As a Healthcare name, CUE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CUE-specific events.
CUE straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CUE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CUE alongside the broader basket even when CUE-specific fundamentals are unchanged. Always rebuild the position from current CUE chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on CUE?
- A straddle on CUE is the straddle strategy applied to CUE (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With CUE stock trading near $30.36, the strikes shown on this page are snapped to the nearest listed CUE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CUE straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the CUE straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 43.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CUE straddle?
- The breakeven for the CUE straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CUE market-implied 1-standard-deviation expected move is approximately 12.56%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on CUE?
- Straddles on CUE are pure-volatility plays that profit from large moves in either direction; traders typically buy CUE straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current CUE implied volatility affect this straddle?
- CUE ATM IV is at 43.80% with IV rank near 10.60%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.